This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): elvitegravir/cobicistat/emtricitabine/tenofovir, elvitegravir/cobicistat/Emtriva/Viread, Quad
Description: Quad is a single pill combination of a reverse transcriptase inhibitor (Truvada, which consists of both emtricitabine and tenofovir), an HIV integrase inhibitor (Elvitegravir) and a booster to allow for less frequent dosing (Cobicistat).
Gilead and Japan Tobacco
In July 2003, Gilead announced that the company has entered into a licensing agreement with Japan Tobacco (JT) under which JT will commercialize products in Gilead's HIV portfolio in Japan. The agreement includes Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and a future co-formulation of the two products. Under the terms of the agreement, Gilead will receive an up-front fee and is entitled to receive additional cash payments upon achievement of certain milestones. JT also will make payments to Gilead based on product sales. JT will submit applications for Viread and Emtriva to Japanese regulatory authorities in the near future.
Elvitegravir was discovered by Japan Tobacco and licensed to Gilead in March 2005. The license granted Gilead exclusive rights to develop and commercialize Elvitegravir in all countries of the world, excluding Japan where Japan Tobacco will retain rights.
Gilead and Mylan
In January...See full deal structure in Biomedtracker
Partners: Japan Tobacco Inc. Mylan Inc.
Additional information available to subscribers only: